University of Miami Health System, Miller School of Medicine

University of Miami Treats COVID-19 Patients with MSC Stem Cells

For COVID-19 patients in severe respiratory distress, the University of Miami Miller School of Medicine now offers access to mesenchymal stem cell (MSC) treatments that may help fight the characteristic inflammation that accompanies the viral infection.

Newswise — For COVID-19 patients in severe respiratory distress, the University of Miami Miller School of Medicine now offers access to mesenchymal stem cell (MSC) treatments that may help fight the characteristic inflammation that accompanies the viral infection.

On April 5, the U.S. Food and Drug Administration (FDA) approved MSC treatments for seriously ill COVID-19 patients as an “expanded access compassionate use.” Since then, UM has provided clinicians in Miami and Maryland with MSCs taken from bone marrow and cultured at the Interdisciplinary Stem Cell Institute (ISCI) manufacturing lab. Six COVID-19 patients with serious breathing difficulties have shown improvement after receiving MSC infusions along with other treatments. The sixth patient, who was on ECMO, was recently injected at Jackson Memorial Hospital.

“Early reports from China indicated that MSCs could be helpful in treating COVID-19 patients in severe respiratory distress,” said Jose Guillermo Castro, M.D., professor of infectious diseases at the Miller School and director of the antibiotic stewardship program at UHealth Tower. “We offer that form of therapy through ISCI and are cautiously optimistic that it can be helpful.”

Aisha Khan, executive director of laboratory operations at ISCI, said MSCs can help address an immune system over-response to a COVID-19 infection called a “cytokine storm,” referring to small proteins that produce inflammation, damaging the lungs and other organs. “Stem cells don’t make the virus disappear, but they help the body fight this disease,” said Khan. “By suppressing the cytokine storm, they can help a patient regain breathing ability.”

On April 7, Sixto Alejandro Arias, M.D., an interventional pulmonologist with UHealth – the University of Miami Health System, gave an initial infusion of MSCs to a patient in his 40s, who tested positive for COVID-19 in mid-March and was admitted to UHealth Tower with severe respiratory problems.

“Stem cells have been widely used to treat interstitial lung disease, and we felt this could be a safe and helpful therapy,” said Dr. Arias. “He received other forms of treatment as well; we don’t know how much the MSCs helped his condition. But we are very gratified to see him improve, and he is now out of intensive care.” That patient has since been discharged from UHealth Tower.

In early April, ISCI shipped MSCs to clinicians at the University of Maryland who were treating two patients with no other options. Both initial patients and two additional patients did well, and their levels of inflammation went down, according to Khan.

“We are so pleased to be able to offer this experimental therapy, working closely with our colleagues on the front lines taking care of these critically ill patients,” said Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine and founding director of ISCI.

Khan said ISCI is making both bone marrow and umbilical cord-derived MSCs available for treating COVID-19 patients throughout South Florida. The FDA recently approved a clinical trial led by UM’s Diabetes Research Institute and Cell Transplant Center that will test the safety and effectiveness of umbilical cord-derived MSCs.

“Our staff members are working night and day to build our inventory, and we now have the ability to treat about 50 patients,” Khan said. “We plan to continue growing our inventory because the need for COVID-19 treatments is so great.”



Filters close

Showing results

110 of 5809
Newswise: 267646_web.jpg
Released: 11-Jun-2021 2:10 PM EDT
Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing
Elsevier

The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints.

Released: 11-Jun-2021 1:25 PM EDT
Physical Activity May Curb Health Care Worker Burnout
University of Georgia

More physical activity programming could mitigate the effects of stress and improve worker mental and emotional health.

Newswise: AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
9-Jun-2021 6:05 PM EDT
AI Predicts How Patients with Viral Infections, Including COVID-19, Will Fare
University of California San Diego Health

UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.

Released: 10-Jun-2021 5:35 PM EDT
Senolíticos reducen síntomas de COVID-19 en estudios preclínicos
Mayo Clinic

Los investigadores de Mayo Clinic y sus colegas de la Universidad de Minnesota demostraron que la COVID-19 exacerba las consecuencias nocivas de las células senescentes en el cuerpo. En estudios preclínicos, los fármacos senolíticos descubiertos en Mayo redujeron considerablemente la inflamación, la enfermedad y la mortalidad debida a la infección por covid en ratones ancianos. Los resultados se publican en la revista Science.

Released: 10-Jun-2021 5:30 PM EDT
Senolíticos reduzem os sintomas de COVID-19 em estudos pré-clínicos
Mayo Clinic

Os pesquisadores da Mayo Clinic e colegas da Universidade de Minnesota mostraram que o COVID-19 intensifica o impacto prejudicial das células senescentes no corpo. Em estudos pré-clínicos, os medicamentos senolíticos descobertos na Mayo reduziram significativamente a inflamação, a gravidade da doença e a mortalidade da infecção por COVID em camundongos mais velhos. Essas conclusões foram publicadas na revista Science.

Newswise: FresnoSTateVaxImage2.jpg
Released: 10-Jun-2021 5:25 PM EDT
CSU Campuses Join COVID-19 College Vaccine Challenge
California State University (CSU) Chancellor's Office

The CSU pledges to be a Vaccine Champion University as part of new White House effort aimed at increasing vaccinations for younger Americans.

Released: 10-Jun-2021 5:05 PM EDT
الأدوية المحللة للشيخوخة تقلل من أعراض فيروس كورونا المستجد (كوفيد-19) في الدراسات ما قبل السريرية
Mayo Clinic

أظهر باحثو مايو كلينك وزملاؤهم في جامعة مينيسوتا أن فيروس كورونا المستجد (كوفيد-19) يفاقم التأثير الضار للخلايا الشائخة في الجسم. ففي الدراسات ما قبل السريرية، قللت الأدوية المحللة لالشيخوخة التي تم اكتشافها في مايو بشكل كبير من الالتهاب والمرض والوفيات الناجمة عن عَدوى فيروس كورونا المستجد في الفئران الأكبر سنًا. النتائج منشورة في مجلة ساينس.

7-Jun-2021 7:05 AM EDT
Study Examines the Effects of COVID-19 on Human Kidney Cells
American Society of Nephrology (ASN)

• The virus that causes COVID-19 can infect and replicate in human kidney cells, but this does not typically lead to cell death. • Kidney cells that already have features of injury may be more easily infected and develop additional injury.

Released: 10-Jun-2021 4:55 PM EDT
抗衰老药物在临床前研究中减少COVID-19症状。
Mayo Clinic

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

Newswise: blobid0_1623274320110.jpg
Released: 10-Jun-2021 4:45 PM EDT
How does COVID-19 affect patients with cancer? Largest U.S. study shares first results
University of Alabama at Birmingham

New findings include a significant increase in risk of death among patients who had recently had chemotherapy.


Showing results

110 of 5809

close
3.03034